Eos Biosciences, Inc. and Cedars-Sinai Medical Center sign a license agreement, providing Eos Biosciences with an exclusive world-wide license to a novel and innovative drug-targeting platform technology developed by Dr. Lali Medina-Kauwe at Cedars-Sinai Medical Center. The agreement covers nanopartical technology patent rights for use in the prevention, treatment or diagnosis of diseases.